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DANCE ROUND
We dance round in a ring and suppose,
But the Secret sits in the middle and knows.
Robert Frost
It is known today that low grade inammatory mechanisms play 
a pivotal role in the pathogenesis of cardiometabolic diseases in-
cluding the metabolic syndrome (1-4). In the same vein, in ad-
dition to its role in cholinergic neurotransmission, acetylcholine 
exerts a potential anti-inammatory eect mediated by “cho-
linergic anti-inammatory reex” (5). Accordingly, a positive 
correlation of the blood serum level of acetylcholinesterase, bu-
tyrylcholinesterase and C-reactive protein (CRP) was reported 
in obese and diabetic patients (6-10).
In the present study we measured serum levels of acetylcho-
linesterase, an enzyme hydrolizing acetylcholine, and  CRP, a 
known inammatory marker,  in patients with mild stage (n=14) 
and with advanced stage (n=14) of metabolic syndrome, accord-
ing to the criteria of the United States National Cholesterol Edu-
cation Program’s Adult Treatment Рanel III (ATP III). e con-
trol group comprised of age- and sex-matched healthy subjects 
(n=7). 
In patients with advanced metabolic syndrome both acetyl-
cholinesterase and CRP serum level was signicantly elevated 
as compared to that in mild metabolic syndrome patients and 
in controls.
In mild metabolic syndrome acetylcholinesterase level was in 
the range of 8 972 U/L, a similar to that in controls.  Whereas 
in advanced metabolic syndrome the level of acetylcholinest-
erase was signicantly increased: 12 000 U/L ± [F(1.26)=31.96, 
p<0.01] (Fig. 1); this correlated with the elevated CRP level (data 
not shown).
Since the increased acetylcholinesterase serum level may 
serve as a biomarker for the progression of inammation in 
metabolic syndrome, the inhibitors of acetylcholinesterase as 
well as agonists of nicotinic acetylcholine receptors (11) may 
open new eld of research on the pharmacotherapy of metabolic 
syndrome. 
We have previously reported that the circulating levels of 
both nerve growth factor (NGF) и brain-derived neurotrophic 
factor (BDNF) were signicantly reduced in patients with ad-
vanced metabolic syndrome (12, 13).  Since cholinergic anti-
inammatory control is compromised in diabetes and metabolic 
syndrome (6-10 and the present data) and in Alzheimer’s disease 
Figure 1. Serum levels (in U/L) of acetylcholinesterase in pa-
tients with mild and advanced metabolic syndrome as com-
pared to controls. 
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(14, 15) and since NGF and BDNF are also implicated in the 
pathogenesis of cardiometabolic and neurodegenerative diseas-
es (16, 17), further studies are required on the possible role of 
NGF/BDNF and  acetylcholinesterase/CRP in the development 
of these diseases. 
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